News in Drug-Eluting Stents. Update and Future Developments;Novedades en farmacoactivos. Actualización y futuros desarrollos

Revista Espanola de Cardiologia Suplementos

Volumn 10, Issue SUPPL. 3, 2010, Pages

  Serra Peñaranda, Antonio ^a   Guardiola, Faustino Miranda ^b   Montilla, Beatriz Vaquerizo ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Bio active stent; Biodegradable stent; Biodegradable polymer stent; Biolimus A9; Drug eluting stent; Polymer

Indexed keywords

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; DRUG ELUTING STENT; DRUG SAFETY; MEDICAL RESEARCH;

EID: 78650332523     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(10)70018-2     Document Type: Article

References (16)

1. Finn A.V., Vorpahl M., Ladich E., Virmani R. Future directions in stenting. Expert Rev Cardiovasc Ther 2010, 8:1-6.
2. Nakazawa G., Finn A.V., Kolodgie F.D., Virmani R. A review of current devices and a look at new technology: drug-eluting stents. Expert Rev Med Devices 2009, 6:33-42.
3. Ramcharitar S., Serruys P.W. Fully biodegradable coronary stents. Progress to date. Am J Cardiovasc Drugs 2008, 8:305-314.
4. Duckers H.J., Soullié T., Den Heijer P., Rensing B., De Winter R.J., Rau M., et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent). EuroIntervention 2007, 3:350-358.
5. Serra A., Miranda-Guardiola F., Venegas R. Análisis y características de los stents farmacoactivos disponibles en la actualidad. Futuros desarrollos. Rev Esp Cardiol Supl 2007, 7:E8-28.
6. O'Brien B., Carroll W. The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: A review. Acta Materialia 2009, 5:945-958.
7. Schmidt W., Lanzer P., Behrens P., Topoleski L.D., Schmitz K.P. A comparison of the mechanical performance characteristics of seven drug-eluting stent systems. Catheter Cardiovasc Interv 2009, 73:350-360.
8. Stone G.W., Rizvi A., Newman W., Mastali K., Wang J.C., Caputo R., et al. for the SPIRIT IV Investigators. TCT 2009 abstract: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents: one-year clinical outcomes from the SPIRIT IV trial. Am J Cardiol 2009, 140:XV.
9. Kedhi E., Joesoef K.S., McFadden E., Wassing J., Van Mieghem C., Goedhart D., et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010, 375:201-209.
10. Meredith I.T., Worthley S., Whitbourn R., Walters D.L., McClean D., Horrigan M., et al. for the RESOLUTE Investigators. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-inhuman trial. JACC Cardiovasc Interv 2009, 2:977-985.
11. Meredith I.T., Worthley S., Whitbourn R., Walters D.L., McClean D., Horrigan M., et al. for the RESOLUTE Investigators. Longterm clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. EuroIntervention 2010, 5:692-697.
12. Windecker S., Serruys P.W., Wandel S., Buszman P., Trznadel S., Linke A., et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008, 372:1163-1173.
13. Chevalier B., Silber S., Park S.J., Garcia E., Schuler G., Suryapranata H., et al. NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial -Phase 2. Circ Cardiovasc Interv 2009, 2:188-195.
14. Ruef J., Störger H., Schwarz F., Haase J. Increased restenosis rates 12 months after coronary implantation of the sirolimuseluting YUKON -choice stent compared to the paclitaxeleluting TAXUS stent. Clin Cardiol 2010, 33:E33-E38.
15. Cervinka P, Bystron M, Spacek R, Kvasnak M, Jakabcin J. Randomized comparison of Genous stent versus Chromium-Cobalt stent for treatment of ST elevation myocardial infarction. 6 months clinical angiographic and IVUS followup. GENIUS-STEMI trial. Presentado en: ACC I2 Summit 2009. Orlando, 28 de marzo de 2009.
16. Karjalainen P.P., Annala A.P., Ylitalo A., Vahlberg T., Airaksinen K.E. Long-term clinical outcome with titanium-nitrideoxide- coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. Int J Cardiol 2009, Abril 27 [Epub ahead of print].